Home / Sermorelin vs Tesamorelin
ComparisonGHRH AnalogsGH Peptides

Sermorelin vs Tesamorelin:
Which GHRH Peptide for Your Research?

Both stimulate endogenous GH secretion — but they have different structures, half-lives, clinical data, and research applications. Here's how to think about the choice.

10 min read
📊 Side-by-side tables
📅 Updated April 2026
Jump toBottom LineStructureComparisonClinical DataWhich to UseFAQ
Bottom Line First

The Short Answer

Both sermorelin and tesamorelin are GHRH analogs that stimulate endogenous GH secretion, but they were developed for different purposes and have meaningfully different profiles. Sermorelin is a shorter fragment with a rapid pulse, extensive pediatric clinical data, and broad GH-deficiency research applications. Tesamorelin is a stabilized full-length GHRH analog with FDA approval specifically for visceral adiposity in HIV-associated lipodystrophy, backed by randomized controlled trial data for visceral fat reduction.

29
Sermorelin (aa)
44
Tesamorelin (aa)
~11 min
Sermorelin t½
~26 min
Tesamorelin t½
The Science

Structural Differences That Matter

Sermorelin is GHRH(1-29)-NH₂ — the 29-amino-acid N-terminal fragment of endogenous GHRH, amidated at the C-terminus. This fragment retains full GHRH receptor binding activity. The shorter sequence makes it faster to clear and produces a sharp, pulsatile GH response.

Tesamorelin is a synthetic analog of the full 44-amino-acid GHRH, modified with a trans-3-hexenoic acid group at the N-terminus. This modification substantially increases resistance to dipeptidyl peptidase IV (DPP-IV) degradation, extending its half-life from about 7 minutes (native GHRH) to approximately 26 minutes. The result is a longer, more sustained GH stimulus per injection.

Why the Modification Matters

Endogenous GHRH is rapidly cleaved by DPP-IV. Tesamorelin's N-terminal modification specifically blocks this cleavage site, explaining its longer half-life and the more sustained IGF-1 response seen in clinical trials versus sermorelin.

Head to Head

Side-by-Side Comparison

FactorSermorelinTesamorelin
StructureGHRH(1-29)-NH₂GHRH(1-44) + trans-3-hexenoic acid
Half-life~11 minutes~26 minutes
GH response patternSharp pulseMore sustained
IGF-1 increaseModerateMore pronounced
FDA approvalGH deficiency (pediatric, 1997, discontinued)HIV lipodystrophy visceral fat (2010, active)
Visceral fat dataLimited direct RCT dataStrong Phase 3 RCT data
Typical dose200–500 mcg/day2mg/day
Typical cycle3–6 months6–12 months
CostLowerHigher
Clinical historyExtensive (pediatric)Strong (adult visceral fat)
Research Data

What the Clinical Data Shows

Sermorelin's Strengths

Sermorelin has the deeper clinical history. Its pediatric GH deficiency data spans decades, with comparative trials against recombinant HGH showing similar height velocity outcomes. In adult somatopause research, sermorelin has demonstrated reliable IGF-1 restoration and body composition improvements over 6-month periods.

Tesamorelin's Strengths

Tesamorelin's data is more targeted but arguably more rigorous for its specific application. The Phase 3 LIPO trials demonstrated a 15–18% reduction in visceral adipose tissue (VAT) over 26 weeks in HIV-positive subjects with lipodystrophy — the data package that earned FDA approval for Egrifta. Subsequent research has explored tesamorelin in non-HIV populations with visceral adiposity and in cognitive aging research (ongoing TREAT trial data).

For General GH Optimization Research

The two compounds are more similar than different when used for general somatopause or GH optimization research. Tesamorelin produces higher, more sustained IGF-1 elevation; sermorelin produces a more physiological pulsatile pattern. Neither has been directly compared head-to-head in a rigorous RCT for this application.

Decision Framework

Which Fits Your Research Goals?

Research GoalLean TowardWhy
GH deficiency researchSermorelinMore established literature, lower cost
Visceral fat reductionTesamorelinDirect Phase 3 RCT data for this endpoint
GH pulsatility restorationSermorelinSharper, more physiological pulse pattern
IGF-1 optimizationTesamorelinMore sustained IGF-1 elevation per dose
Cost-sensitive protocolsSermorelinSignificantly lower cost per cycle
Longer half-life preferredTesamorelin26 min vs 11 min; less frequent peaks
Combination Consideration

Some researchers have explored GHRH analogs alongside GHRP peptides (ipamorelin) regardless of which GHRH analog is used. The GHRH + GHRP synergy appears class-wide — meaning the combination effect applies to both sermorelin and tesamorelin protocols.

View Sermorelin Pricing & Protocol

COA-verified vendor pricing, promo codes, and reconstitution guide.

View Pricing → Dosage Calculator
Common Questions

FAQ

Can sermorelin and tesamorelin be used together?
Using two GHRH analogs simultaneously would occupy the same receptor class without additive benefit — the receptors would be saturated. They are not typically combined. The standard combination is a GHRH analog (either one) plus a GHRP peptide like ipamorelin.
Is tesamorelin worth the higher cost?
If visceral fat reduction is the primary research endpoint, tesamorelin's clinical data is substantially stronger. For general GH optimization research where cost is a factor, sermorelin's longer track record and lower price make it a reasonable choice.
Does tesamorelin work better than sermorelin?
"Better" depends entirely on the research goal. Tesamorelin produces higher IGF-1 elevation and has stronger visceral fat data. Sermorelin produces a more pulsatile GH response and has deeper clinical history. Neither is universally superior.
Research purposes only. Sermorelin is a research compound. This content is for educational reference only and does not constitute medical advice. Consult a licensed physician before use.
Keep Reading

Related Articles